Thromboembolic risk in subcutaneous versus intravenous immunoglobulin therapy: a systematic review and narrative meta-synthesis - PubMed
3 hours ago
- #immunoglobulin therapy
- #thromboembolism
- #systematic review
- Intravenous immunoglobulin (IVIg) therapy is linked to thromboembolic events like DVT, PE, stroke, and MI.
- Subcutaneous immunoglobulin (SCIg) yields lower peak IgG levels and may have a lower thromboembolic risk.
- A systematic review compared thromboembolic safety between SCIg and IVIg across neurological and immunological conditions.
- IVIg had a pooled thromboembolic incidence of 1.8 per 100 patient-years (95% CI: 0.9-3.1).
- SCIg showed a pooled incidence of 0.14 per 100 patient-years (95% CI: 0.01-0.52), with only 3 events in high-risk patients.
- No head-to-head randomized trials exist; evidence certainty is very low due to population and methodological differences.
- Indirect evidence suggests SCIg may be safer, aligning with pharmacokinetic predictions, but definitive conclusions require more research.